LETTERS AND COMMUNICATIONS
Reply: “100 Citation Classics in the Melanoma Literature: A Bibliometric Analysis”—Dermatol Surg 2014;1284–98 We read with interest the article entitled “100 Citation Classics in the Melanoma Literature: A Bibliometric Analysis.”1 We congratulate the authors on conducting the first citation analysis of the melanoma literature. It is important for identifying the most significant contributions to melanoma research. Sixty-four well-renowned journals were included in this study. However, there are still several prestigious international journals not included, such as Cell, Nature, and Science. Through the search strategy described by the authors, articles with number of citations over 309 from 1945 to 2013 have been identified in Cell (4 articles), Nature (10 articles), and Science (11 articles). Because 12 of the 100 citation classics have number of citations less than 309, the addition of Cell, Nature, and Science to the journal list will significantly change the result of this study. For example, the top 100 list will be changed, and the number of journals contributed to the top 100 list will be 25 instead of 22. Most of the top cited articles in those 3 journals were experimental, but there were also clinical studies, such as one Phase 1 clinical trial for BRAF-mutant melanoma.2 One article published in Science has been cited for 2,326 times,
which is an experimental study on potential targeted immunotherapy.3 This article provides a fascinating understanding of the history and development of trends in current melanoma management. We are looking forward to more scientific breakthroughs and landmarks in this field.
References 1. Joyce CW, Sugrue CM, Joyce KM, Kelly JL, et al. 100 citation classics in the melanoma literature: a bibliometric analysis. Dermatol Surg 2014;40: 1284–98. 2. Bollag G, Hirth P, Tsai J, Zhang J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596–9. 3. van der Bruggen P, Traversari C, Chomez P, Lurquin C, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643–7.
Jiuzuo Huang, MD Xiao Long, MD Department of Plastic and Reconstructive Surgery Peking Union Medical College Hospital Beijing, China The authors have indicated no significant interest with commercial supporters.
Utility of MRI in the Diagnosis and Post-Treatment Evaluation of Anogenital Hidradenitis Suppurativa The authors praise Wortsman and colleagues1 along with Zarchi and Jemec2 for their articles focused on the important role of ultrasound examination in identifying the subclinical lesions and optimizing the staging of anogenital hidradenitis suppurativa (HS). The authors would also like readers to consider the use of magnetic resonance imaging (MRI) in advanced cases of anogential HS. As of 2014, resorting to MRI for anogenital HS has been reported only by 2 works.1,2 Although probably underestimated, the contribution
offered by this radiological tool to describing the extent, evolution, or complications of this disease seems to be of great value. The authors’ experience is in keeping with the 2 works previously reported. Recently, in fact, a 57-year-old man was referred to the authors’ surgical department for reacutized purulent anogenital HS. The disease was diagnosed 20 years ago, and the patient had already withstood several surgical interventions in former years. This time, an MRI of the
41:7:JULY 2015
865
© 2015 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Reply: “100 Citation Classics in the Melanoma Literature: A Bibliometric Analysis”—Dermatol Surg 2014;1284–98 We read with interest the article entitled “100 Citation Classics in the Melanoma Literature: A Bibliometric Analysis.”1 We congratulate the authors on conducting the first citation analysis of the melanoma literature. It is important for identifying the most significant contributions to melanoma research. Sixty-four well-renowned journals were included in this study. However, there are still several prestigious international journals not included, such as Cell, Nature, and Science. Through the search strategy described by the authors, articles with number of citations over 309 from 1945 to 2013 have been identified in Cell (4 articles), Nature (10 articles), and Science (11 articles). Because 12 of the 100 citation classics have number of citations less than 309, the addition of Cell, Nature, and Science to the journal list will significantly change the result of this study. For example, the top 100 list will be changed, and the number of journals contributed to the top 100 list will be 25 instead of 22. Most of the top cited articles in those 3 journals were experimental, but there were also clinical studies, such as one Phase 1 clinical trial for BRAF-mutant melanoma.2 One article published in Science has been cited for 2,326 times,
which is an experimental study on potential targeted immunotherapy.3 This article provides a fascinating understanding of the history and development of trends in current melanoma management. We are looking forward to more scientific breakthroughs and landmarks in this field.
References 1. Joyce CW, Sugrue CM, Joyce KM, Kelly JL, et al. 100 citation classics in the melanoma literature: a bibliometric analysis. Dermatol Surg 2014;40: 1284–98. 2. Bollag G, Hirth P, Tsai J, Zhang J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596–9. 3. van der Bruggen P, Traversari C, Chomez P, Lurquin C, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643–7.
Jiuzuo Huang, MD Xiao Long, MD Department of Plastic and Reconstructive Surgery Peking Union Medical College Hospital Beijing, China The authors have indicated no significant interest with commercial supporters.
Utility of MRI in the Diagnosis and Post-Treatment Evaluation of Anogenital Hidradenitis Suppurativa The authors praise Wortsman and colleagues1 along with Zarchi and Jemec2 for their articles focused on the important role of ultrasound examination in identifying the subclinical lesions and optimizing the staging of anogenital hidradenitis suppurativa (HS). The authors would also like readers to consider the use of magnetic resonance imaging (MRI) in advanced cases of anogential HS. As of 2014, resorting to MRI for anogenital HS has been reported only by 2 works.1,2 Although probably underestimated, the contribution
offered by this radiological tool to describing the extent, evolution, or complications of this disease seems to be of great value. The authors’ experience is in keeping with the 2 works previously reported. Recently, in fact, a 57-year-old man was referred to the authors’ surgical department for reacutized purulent anogenital HS. The disease was diagnosed 20 years ago, and the patient had already withstood several surgical interventions in former years. This time, an MRI of the
41:7:JULY 2015
865
© 2015 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
